[Expectations for alendronate in gynecology]

Although the effect of alendronate is slightly less effective than that of hormone replacement therapy in terms of the short-term increase in bone mineral density, alendronate excels with respect to long-term benefits, often persisting after discontinuation of treatment. Alendronate is more effective than hormone replacement therapy in preventing femoral neck fractures and is thus indicated for the long-term prophylaxis of postmenopausal decreases in bone mineral density and for the management of osteoporosis in women who have fractures or an increased fracture risk. Alendronate may become a treatment of first choice for osteoporosis in postmenopausal women. As further evidence of cardiovascular benefits of alendronate becomes available, alendronate is expected to contribute to the overall health care of middle aged and elderly women.